IL6 and renal fibrosis: Tocilizumab is an emerging therapy for conditions mediated by IL-6, and tocilizumab mimotope has demonstrated the ability to alleviate renal fibrosis by inhibiting ferroptosis in the UUO model, presenting a potential alternative therapy for renal fibrosis [101].